Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients
Abstract
Purpose
Pyogenic spondylodiscitis (PS) is a potentially life-threatening infection burdened by high morbidity rates. Despite the rising incidence, the proper management of PS is still controversial. Aim of this study was to describe the clinical features of PS and to evaluate the prognostic factors and the long-term outcomes of a large population of patients.
Methods
207 cases of PS treated from 2008 to 2016 with a 2-year follow-up were enrolled. Clinical data from each patient were recorded. The primary outcome was the rate of healing without residual disability. Secondary outcomes included length of stay, healing from infection, death, relapse, and residual disability. Binomial logistic regression and multivariate analysis were used to evaluate prognostic factors.
Results
Median diagnostic delay was 30 days and the rate of onset neurological impairment was 23.6%. Microbiological diagnosis was established in 155 patients (74.3%) and the median duration of total antibiotic therapy was 148 days. Orthopedic treatment was conservative for 124 patients and surgical in 47 cases. Complete healing without disability was achieved in 142 patients (77.6%). Statistically confirmed negative prognostic factors were: negative microbiological culture, neurologic impairment at diagnosis and underlying endocarditis (p ≤ 0.05). Healing from infection rate was 90.9%, while residual disabilities occurred in 23.5%. Observed mortality rate was 7.8%.
Conclusion
The microbiological diagnosis is the main predictive factor for successful treatment. Early diagnosis and multidisciplinary management are also needed to identify underlying aggressive conditions and to avoid neurological complications associated with poorer long-term outcomes. Despite high healing rates, PS may lead to major disabilities still representing a difficult challenge.
Graphical abstract
Keywords
Spondylodiscitis Prognostic factors Outcomes Antibiotic therapy Orthopedic treatmentNotes
Acknowledgements
The authors declare that they received no grants or funding.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Supplementary material
References
- 1.Grammatico L, Baron S, Rusch E, Lepage B, Surer N, Desenclos JC, Besnier JM (2008) Epidemiology of vertebral osteomyelitis (VO) in France: analysis of hospital-discharge data 2002–2003. Epidemiol Infect 136:653–660. https://doi.org/10.1017/s0950268807008850 CrossRefPubMedGoogle Scholar
- 2.Mylona E, Samarkos M, Kakalou E, Fanourgiakis P, Skoutelis A (2009) Pyogenic vertebral osteomyelitis: a systematic review of clinical characteristics. Semin Arthritis Rheum 39:10–17. https://doi.org/10.1016/j.semarthrit.2008.03.002 CrossRefPubMedGoogle Scholar
- 3.Fantoni M, Trecarichi EM, Rossi B, Mazzotta V, Di Giacomo G, Nasto LA, Di Meco E, Pola E (2012) Epidemiological and clinical features of pyogenic spondylodiscitis. Eur Rev Med Pharmacol Sci 16(Suppl 2):2–7PubMedGoogle Scholar
- 4.Skaf GS, Domloj NT, Fehlings MG, Bouclaous CH, Sabbagh AS, Kanafani ZA, Kanj SS (2010) Pyogenic spondylodiscitis: an overview. J Infect Public Health 3:5–16. https://doi.org/10.1016/j.jiph.2010.01.001 CrossRefPubMedGoogle Scholar
- 5.Hopkinson N, Patel K (2016) Clinical features of septic discitis in the UK: a retrospective case ascertainment study and review of management recommendations. Rheumatol Int 36:1319–1326. https://doi.org/10.1007/s00296-016-3532-1 CrossRefPubMedGoogle Scholar
- 6.Krogsgaard MR, Wagn P, Bengtsson J (1998) Epidemiology of acute vertebral osteomyelitis in Denmark: 137 cases in Denmark 1978–1982, compared to cases reported to the National Patient Register 1991–1993. Acta Orthop Scand 69:513–517. https://doi.org/10.3109/17453679808997789 CrossRefPubMedGoogle Scholar
- 7.Kehrer M, Pedersen C, Jensen TG, Lassen AT (2014) Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study. J Infect 68:313–320. https://doi.org/10.1016/j.jinf.2013.11.011 CrossRefPubMedGoogle Scholar
- 8.Akiyama T, Chikuda H, Yasunaga H, Horiguchi H, Fushimi K, Saita K (2013) Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database. BMJ Open 3:e002412. https://doi.org/10.1136/bmjopen-2012-002412 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Lora-Tamayo J, Euba G, Narváez JA, Murillo O, Verdaguer R, Sobrino B, Narváez J, Nolla JM, Ariza J (2011) Changing trends in the epidemiology of pyogenic vertebral osteomyelitis: the impact of cases with no microbiologic diagnosis. Semin Arthritis Rheum 41:247–255. https://doi.org/10.1016/j.semarthrit.2011.04.002 CrossRefPubMedGoogle Scholar
- 10.Nasto LA, Colangelo D, Rossi B, Fantoni M, Pola E (2012) Post-operative spondylodiscitis. Eur Rev Med Pharmacol Sci 16(Suppl 2):50–57PubMedGoogle Scholar
- 11.Duarte RM, Vaccaro AR (2013) Spinal infection: state of the art and management algorithm. Eur Spine J 22:2787–2799. https://doi.org/10.1007/s00586-013-2850-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Kulowski J (1936) The Orr treatment of pyogenic osteomyelitis. Ann Surg 103:613–624CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD, Huddleston PM 3rd, Petermann GW, Osmon DR (2015) Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Infect Dis 61:e26–e46. https://doi.org/10.1093/cid/civ482 CrossRefPubMedGoogle Scholar
- 14.Pola E, Autore G, Formica VM, Pambianco V, Colangelo D, Cauda R, Fantoni M (2017) New classification for the treatment of pyogenic spondylodiscitis: validation study on a population of 250 patients with a follow-up of 2 years. Eur Spine J 26(Suppl 4):479–488. https://doi.org/10.1007/s00586-017-5043-5 CrossRefPubMedGoogle Scholar
- 15.Jean M, Irisson JO, Gras G, Bouchand F, Simo D, Duran C, Perronne C, Mulleman D, Bernard L, Dinh A (2017) Diagnostic delay of pyogenic vertebral osteomyelitis and its associated factors. Scand J Rheumatol 46:64–68. https://doi.org/10.3109/03009742.2016.1158314 CrossRefPubMedGoogle Scholar
- 16.Leone A, Dell’Atti C, Magarelli N, Colelli P, Balanika A, Casale R, Bonomo L (2012) Imaging of spondylodiscitis. Eur Rev Med Pharmacol Sci 16(Suppl 2):8–19PubMedGoogle Scholar
- 17.Ramadani N, Dedushi K, Kabashi S, Mucaj S (2017) Radiologic Diagnosis of Spondylodiscitis, Role of Magnetic Resonance. Acta Inform Med 25:54–57. https://doi.org/10.5455/aim.2017.25.54-57 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Lee IS, Lee JS, Kim SJ, Jun S, Suh KT (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pyogenic and tuberculous spondylitis: preliminary study. J Comput Assist Tomogr 33:587–592. https://doi.org/10.1097/RCT.0b013e318187fef8 CrossRefPubMedGoogle Scholar
- 19.Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru JP, Therby A, Bouhour D, Dénes E, Debard A, Chirouze C, Fèvre K, Dupon M, Aegerter P, Mulleman D (2015) Duration of Treatment for Spondylodiscitis (DTS) study group (2015) Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet 385:875–882. https://doi.org/10.1016/S0140-6736(14)61233-2 CrossRefPubMedGoogle Scholar
- 20.Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY, Lee YM, Chong YP, Kim SH, Lee SO, Choi SH, Bae IG, Kim YS, Woo JH, Lee MS (2016) Optimal duration of antibiotic therapy in patients with hematogenous vertebral osteomyelitis at low risk and high risk of recurrence. Clin Infect Dis 62:1262–1269. https://doi.org/10.1093/cid/ciw098 CrossRefPubMedGoogle Scholar
- 21.Roblot F, Besnier JM, Juhel L, Vidal C, Ragot S, Bastides F, Le Moal G, Godet C, Mulleman D, Azaïs I, Becq-Giraudon B, Choutet P (2007) Optimal duration of antibiotic therapy in vertebral osteomyelitis. Semin Arthritis Rheum 36:269–277CrossRefPubMedGoogle Scholar
- 22.Grados F, Lescure FX, Senneville E, Flipo RM, Schmit JL, Fardellone P (2007) Suggestions for managing pyogenic (non-tuberculous) discitis in adults. Joint Bone Spine 74:133–139CrossRefPubMedGoogle Scholar
- 23.Pola E, Logroscino CA, Gentiempo M, Colangelo D, Mazzotta V, Di Meco E, Fantoni M (2014) Medical and surgical treatment of pyogenic spondylodiscitis. Eur Rev Med Pharmacol Sci 16(Suppl 2):35–49Google Scholar
- 24.Nasto LA, Colangelo D, Mazzotta V, Di Meco E, Neri V, Nasto RA, Fantoni M, Pola E (2014) Is posterior percutaneous screw-rod instrumentation a safe and effective alternative approach to TLSO rigid bracing for single-level pyogenic spondylodiscitis? Results of a retrospective cohort analysis. Spine J 14:1139–1146. https://doi.org/10.1016/j.spinee.2013.07.479 CrossRefPubMedGoogle Scholar
- 25.Turel MK, Kerolus M, Deutsch H (2017) The role of minimally invasive spine surgery in the management of pyogenic spinal discitis. J Craniovertebr Junction Spine 8:39–43. https://doi.org/10.4103/0974-8237.199873 CrossRefPubMedPubMedCentralGoogle Scholar